Table 2 |
|||
|
Baseline characteristics of participants, by reporting mode |
|||
|
Internet |
Telephone |
Total |
|
|
|
|||
|
Completed, n (% of total) |
290 (84.3%) |
54 (15.7%) |
344 (100%) |
|
Completed by: n (%) |
|||
|
Patient |
277 (95.5%) |
54 (100%) |
331 (96.2%) |
|
Carer |
6 (2.1%) |
0 (0%) |
6 (1.7%) |
|
Parent |
7 (2.4%) |
0 (0%) |
7 (2.0%) |
|
Age, mean years (range) |
51.4 (13-77)a |
61.5 (35-82) |
53.1 (13-82) |
|
Sex, n (%) M/F |
103/166 (38.3/61.7) |
19/35 (35.2/64.8) |
122/201 (37.8/62.2) |
|
Diagnosis, n (%) [mean age, %F] |
|||
|
Rheumatoid arthritis |
152 (79.6%) [53.9, 72%] |
39 (20.4)% [64.4, 67%] |
191 (100%)[56.0, 71%] |
|
Psoriasis |
31 (88.6%) [48.2, 52%] |
4 (11.4%) [61.2, 75%] |
35 (100%) [49.8, 62%] |
|
Ankylosing spondylitis |
40 (93.0%)[49.1, 25%] |
3 (7.0%) [51.3, 33%] |
43 (100%) [49.2, 26%] |
|
Psoriatic arthritis |
37 (84.1%) 50.3, 68%] |
7 (15.9%) [51.9, 71%] |
44 (100%) [50.5, 68%] |
|
Otherb |
30 (96.8%) [41.7, 63%] |
1 (3.2%) [48.0, 0%] |
31 (100%) [42.1, 62%] |
|
Previous biologics |
|||
|
N |
275 |
54 |
329 |
|
Any |
59 (21.5%) |
6 (11.1%) |
65 (19.8%) |
|
Adulimumab |
43 (15.6%) |
5 (9.3%) |
48 (14.6%) |
|
Infliximab |
11 (4.0%) |
1 (1.9%) |
12 (3.6%) |
|
Current medications |
|||
|
N |
277 |
54 |
331 |
|
Methotrexate |
120 (43.3%) |
29 (53.7%) |
149 (45.0%) |
|
Sulfasalazine |
46 (16.6%) |
7 (13.0%) |
53 (16.0%) |
|
Prednisolone |
55 (19.9%) |
14 (25.9%) |
69 (20.8%) |
|
Quality of life |
|||
|
CGI-S |
|||
|
N |
275 |
54 |
329 |
|
N ( %) ≥markedly ill) |
184 (66.9%) |
30 (55.6%) |
214 (65.0%) |
|
EQ-5D |
|||
|
N |
265 |
54 |
(0.35) |
|
EQ5D Index, Mean (SD) |
0.41 (0.36) |
0.45 (0.29) |
0.42 |
|
N |
139 |
20 |
159 |
|
EQ5D VAS, Mean (SD) |
47.6 (23.0) |
51.2 (21.8) |
48.1 (22.8) |
|
HAQ |
|||
|
N |
151 |
190 |
|
|
Mean (SD) |
1.68 (0.64)c |
1.97 |
1.74 (0.65) |
|
DLQI |
|||
|
N |
31 |
4 |
35 |
|
Mean (SD) |
15.5 (8.1) |
11.8 (3.4) |
15.0 (7.8) |
|
|
|||
|
a Statistically significant difference between Internet and telephone users, p < 0.001 (Wilcoxon test) b Includes patients with juvenile idiopathic arthritis (n = 9, 2.6%), patients responding other or not sure of condition (n = 10, 2.9%) and patients with condition missing (n = 12, 3.5%) to the question 'What condition do you have that is being treated with Enbrel?' c Statistically significant difference between Internet and telephone users, p = 0.003 (Wilcoxon test), p = 0.010 (t-test) |
|||
|
Wade et al. BMC Medical Research Methodology 2011 11:91 doi:10.1186/1471-2288-11-91 |
|||
